About
Klaus Dembowsky has been CEO of amcure since 2015. He has over 25 years of experience in research and development for pharmaceutical and biotech companies and a track record of successfully bringing innovative drugs into clinical development and to the market. He worked for more than 10 years at Bayer’s research institute and served in different management positions in the biotech industry, as VP Drug Discovery at Ingenium Pharmaceuticals, Managing Director at Speedel Experimenta, and Chief Medical Officer at Polyphor. Dr. Dembowsky received his medical degree from the University of Heidelberg and habilitated in neurophysiological research in 1988.
Position in the VCSift Database
- • 3 investors at amcure are tracked.
- • 3,360 investors hold the CEO role in VCSift. Klaus Dembowsky is one of them.
- • 845 investors are based in Munich, Bayern, Germany.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Munich, Germany
Contact Information
linkedin.com/in/••••••••
Find more investors like Klaus
Search Investors